key: cord-0965744-u89484ji
authors: Bensouna, Ilias; Caudwell, Valérie; Kubab, Sabah; Acquaviva, Sandra; Pardon, Agathe; Vittoz, Nathalie; Bozman, Dogan-Firat; Hanafi, Latifa; Faucon, Anne-Laure; Housset, Pierre
title: SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis
date: 2021-09-08
journal: Am J Kidney Dis
DOI: 10.1053/j.ajkd.2021.08.005
sha: 2b6482c302bbcabdd3efba2bad48556a59452635
doc_id: 965744
cord_uid: u89484ji

RATIONALE & OBJECTIVE: Recent studies showed that antibody titers after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the dialysis population are diminished as compared to the general population, suggesting the possible value of a third booster dose. We aimed to characterize the humoral response after three doses of the BNT162b2 vaccine in patients treated with either maintenance hemodialysis (HD) or peritoneal dialysis (PD). STUDY DESIGN: Case series. SETTING & PARTICIPANTS: 69 French patients (38 HD and 31 PD) treated at a single center who received three doses of the BNT162b2 vaccine. FINDINGS: Humoral response was evaluated using plasma levels of anti-SARS-CoV-2 spike protein S1 immunoglobulin measured after the second dose and at least three weeks after the third dose of the BNT162b2 vaccine. Patients (median age 68 [IQR, 53-76] years, 65% men) had a median anti-S1 antibody level of 284 [IQR, 83-1190] AU/mL after the second dose, and 7554 [IQR, 2268-11736] AU/mL after the third dose. Three patients were non-responders (anti-S1 antibody level < 0.8 AU/mL) and 12 were weak responders (anti-S1 antibody level 0.8-50 AU/mL) after the second vaccine dose. After the third dose, one of the three initial non-responders produced anti-spike antibody and all the 12 initial weak responders increased their antibody levels. Patients with a greater increase in anti-S1 antibody levels after a third dose had lower antibody levels after the second dose, and a longer time interval between the second and the third dose. Adverse events did not seem to be more common or severe following a third vaccine dose. LIMITATIONS: Observational study, small sample size. Relationship between antibody levels and clinical outcomes is not well understood. CONCLUSIONS: A third dose of the BNT162b2 vaccine substantially increased antibody levels in patients receiving maintenance dialysis and appeared to be as well tolerated as a second dose.

Findings: Humoral response was evaluated using plasma levels of anti-SARS-CoV-2 spike protein S1 immunoglobulin measured after the second dose and at least three weeks after the third dose of the BNT162b2 vaccine. Patients (median age 68 [IQR, 53-76] years, 65% men) had a median anti-S1 antibody level of 284 [IQR, 83-1190] AU/mL after the second dose, and 7554 [IQR, 2268-11736] AU/mL after the third dose. Three patients were non-responders (anti-S1 antibody level < 0.8 AU/mL) and 12 were weak responders (anti-S1 antibody level 0.8-50 AU/mL) after the second vaccine dose. After the third dose, one of the three initial non-responders produced anti-spike antibody and all the 12 initial weak responders increased their antibody levels. Patients with a greater increase in anti-S1 antibody levels after a third dose had lower antibody levels after the second dose, and a longer time interval between the second and the third dose. Adverse events did not seem to be more common or severe following a third vaccine dose.

Observational study, small sample size. Relationship between antibody levels and clinical outcomes is not well understood. 

Since April 2021, the French National Authority for Health has recommended systematic use of third dose of COVID-19 vaccine for dialysis patients to boost immunity. This study assessed vaccine response after the second and third doses by measuring patients' antibody levels. Although most of the patients produced antibodies after two vaccine doses, some of them (mainly elderly and patients receiving treatments that suppress immunity) had relatively low antibody levels. After a third booster dose, almost all patients increased their antibody levels, especially when the third dose was delayed. A third dose was not associated with greater side effects than the second dose. The relationship between increased antibody levels following a third dose and protection against clinical illness with COVID-19 remains to be evaluated. Since the beginning of the epidemic, several vaccines have been approved to prevent acute respiratory distress syndrome induced by SARS-CoV-2. Among them, the BNT162b2 messenger RNA vaccine (Pfizer-BioNTech) is widely used in France, especially in hospitals, where it is possible to store the doses at a sufficiently low temperature. A two-dose regimen of BNT162b2 vaccine is 95% effective in preventing coronavirus disease 2019 in the general population 6 . It was reported in recent case series of dialysis patients vaccinated with BNT162b2 that seroconversion occurred in almost all patients although the antibody titer was lower than in controls [7] [8] [9] [10] [11] [12] [13] . On this basis, it has been recommended by the French National Authority for Health (Haute Autorité de Santé) to systematically administer a third vaccine dose in dialysis patients 14 . Recently, two small case series evaluating humoral response after a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients showed an increase in antibody titer in some patients 15, 16 . In dialysis patients, just one study addressed the humoral response after a third vaccine dose, but only in HD patients with a weak initial response, who showed an increase in antibody titer 17 . J o u r n a l P r e -p r o o f 5 The aims of this study were i) to assess the humoral response after a third dose of the BNT162b2 vaccine both in HD and PD patients, ii) to identify potential factors associated with vaccine response, and iii) to determine if a third dose is associated with adverse events.

Following recommendation from the French National Authority for Health, vaccination of all dialysis patients began in January 2021. In April 2021, the systematic use of a third vaccine dose at least four weeks after the second dose was recommended in dialysis patients.

Between January 13 th and May 18 th 2021, all HD and PD adult patients of the Nephrology Department of the Centre Hospitalier Sud-Francilien (Corbeil-Essonnes, France), who received three doses of the BNT162b2 vaccine were eligible for the study. We excluded patients who died before vaccination (n=1), those who did not consent to vaccination (n=2) or to a third dose (n=1), patients who did not receive a third dose because of symptomatic COVID-19 before the first dose (n=3) or after the second dose (n=4), patients who did not have serology results before (n=2) or after (n=10) the third dose, and those who received a kidney transplant (n=1) before the third dose. Sixty-nine dialysis patients (38 HD and 31 PD patients) had none of these exclusion criteria and were analyzed (Figure 1 ). According to the French legislation (Loi Jardé), anonymous retrospective studies do not require institutional review board approval. All patients provided oral informed consent.

Clinical data, laboratory tests routinely performed in dialysis patients, and dialysis dose (measured by Kt/V) were collected from medical records. The level of immunosuppression was evaluated using gamma globulin concentration and lymphocyte and neutrophilic polymorphonuclear leukocyte counts. A history of hemopathy (plasma cell J o u r n a l P r e -p r o o f 6 dyscrasia), and chemotherapy or immunomodulatory treatment (any treatment during the last year or prednisone ≥ 7.5 mg/d during ≥3 months during the last year) was also collected.

Nutritional status was assessed by body mass index (calculated from the dry weight) and levels of serum albumin and prealbumin; inflammation was assessed by C-reactive protein level. When available, anti-nucleocapsid serology attesting a previous contact with SARS-CoV-2 was also collected.

Humoral response was assessed by the plasma concentration of anti-SARS-CoV-2 spike protein S1 total immunoglobulin antibodies (including IgG, IgM and IgA), which are induced by vaccination, using the Roche Elecsys Assay 18 ; testing was performed after the second dose and at least three weeks after the third vaccine dose. As the measurement range of this assay is of 0 to 250 arbitrary units per milliliter (AU/mL), samples giving results in excess of 250 AU/mL were diluted. According to the manufacturer's protocol, patients with a antibody level below 0.8 AU/mL were considered non-responders. Patients with a level between 0.8 and 50 AU/mL were defined as weak responders, as previously reported 15 .

To assess humoral response after the third vaccine dose, we calculated the ratio of the antibody level measured after the third vaccine dose to the level measured after the second dose, and analyzed in tertiles of increasing ratio (thus the first tertile has the lowest increase in antibody level between the second and the third dose). Patients with initial negative serology were excluded from the analysis, as by definition the ratio could not be calculated.

A questionnaire was provided to all patients to collect vaccine reactions after the third vaccine dose (Item S1). Overall experience with the third dose as compared to the second dose was self-reported by the patient. We also reported hospitalizations and visits to J o u r n a l P r e -p r o o f 7 Emergency Department within the 30 days following the administration of the third vaccine dose.

Categorical variables are reported as frequencies and percentages, and continuous variables are reported as median [interquartile range]. Patients' characteristics were compared according to antibody response (< or ≥50AU/mL) after the second and the third dose, and according to antibody increase after the third dose (across tertiles of the ratio of antibody levels measured after the third and second doses), using the Fisher exact test or the Mann Whitney U test (or using the Kruskal-Wallis test, as appropriate), for qualitative and quantitative variables, respectively. A 2-tailed P value < 0.05 was considered statistically significant. All statistical analyses were conducted using R 3.6 software (R Foundation for Statistical Computing).

Among the 69 patients included, the median age was 68 [IQR, 53-76] years, 65% were men, and dialysis vintage was 3 [IQR, 1-6] years. Twelve patients (17%) had a history of plasma cell dyscrasia and/or immunosuppressive therapy. The median interval between administration of the second BNT162b2 vaccine dose and the first serology was 50 [IQR, 31-58] days. Overall, after two doses, the median anti-S1 antibody level was 284 [IQR, 83-1190] AU/mL ( Table 1) . Three patients (4%) were non-responders and 12 patients (17%) were weak responders (Table S1 ). Factors associated with no or weak response after two doses included an older age, a history of immunosuppressive therapy, a lower lymphocyte count, a lower serum pre-albumin level, and a lower serum gamma globulin level (Table 1) . No difference was found according to dialysis modality.

Humoral response after three vaccine doses J o u r n a l P r e -p r o o f 8 After three vaccine doses, there was a significant increase in antibody level, with a median anti-S1 antibody level of 7554 (IQR, 2268-11736) AU/mL after a median interval between the third dose and serology of 30 (IQR, 27-36) days (Figure 2; Figure S1 ). Only six patients did not increase their antibody level (two remained seronegative, two already had a very high antibody level, and two had a slight decrease) (Table S2) .

Among the three non-responders after the second dose, only one produced anti-S1 antibody after the third dose. All the 12 weak responders increased their antibody level after the third dose, but one remained below the 50 AU/mL threshold (Table S1 ). All responders after the second dose were still seropositive at one month after the third vaccine dose.

Factors associated with no or weak response after three doses included a history of immunosuppressive therapy, a history of hemopathy, a lower serum gamma globulin level, and an initial lower anti-S1 antibody level after two doses (Table S3) . No difference between HD and PD patients was found.

Patients who had the higher increase in anti-S1 antibody level had an initial lower (Table 2, Figure 3) .

Analysis of the anti-nucleocapsid serology status showed that seropositive patients were younger than those were seronegative; they also displayed higher anti-S1 antibody levels after the second dose and a lower increase after third dose (Table S4) . (Figure 4) . In the 30 days following the third vaccine dose, six patients were hospitalized (causes were three bacterial and one aseptic peritonitis in PD patients, one pulmonary embolism, and one osteitis) and two visited the Emergency department (one for chest pain and another one for fatigue) (Table S5) .

No case of COVID-19 was diagnosed after the third vaccine dose, during a median follow-up of 30 days. In contrast, four patients developed symptomatic COVID-19 after the second vaccine dose and therefore were not included: two patients whose antibody levels were not available, one with anti-S1 antiboy level of 709 AU/ml, and another one with a negative serology after the two vaccine doses. Because this last patient was at high risk of complications, he received monoclonal antibodies 4 days after symptom onset. All patients developed mild symptoms and had favorable outcomes.

In this study, we describe the humoral response measured a median of 30 days after the third injection of the BNT162b2 vaccine in 69 patients on maintenance HD or PD.

Administration of a third vaccine dose to dialysis patients substantially increased anti-S1 antibody level, with acceptable vaccine reaction and overall self-reported tolerance similar to second dose. No case of COVID-19 was reported.

Most of the weak responders after the second dose had a history of immunosuppression. Three patients in our HD series with plasma cell dyscrasia (two myeloma and one amyloid light-chain amyloidosis) were undergoing chemotherapy at the time of vaccination. Two of them were non-responders and the remaining patient was a weak responder after two vaccine doses. After a third dose, the two non-responders had still no detectable antibodies and the remaining patient showed a 2.4-fold increase.

These results suggest an impact of comorbidities and immunosuppressive therapy on vaccine response in dialysis patients. They confirm a poor vaccine response in patients under therapy for hemopathy. A recent study reported that up to 48% of patients with myeloma under therapy developed a positive antibody response after SARS-CoV-2 vaccine 19 . A third dose seems to have little or no effect in these patients, although this has to be confirmed, given the small sample size. Whether a higher anti-S1 antibody level titer confers better protection against COVID-19 remains to be determined. A recent study showed a correlation between post vaccination anti-S1 antibodies and neutralizing antibodies 22 implying a protective antibody response. It was also shown that the antibody titer after infection in healthcare workers was inversely correlated with the risk of reinfection 23 . Another study showed that in patients who received J o u r n a l P r e -p r o o f 11 convalescent plasma therapy, a higher antibody titer was associated with a lower risk of death 24 . These results highlight the importance of the humoral response in COVID-19.

The clinical efficacy of a third vaccine dose could not be determined in our study. No case of COVID-19 was diagnosed after the third vaccine dose in our center but follow up was limited to a median of 30 days and during a period with decreased incidence of COVID-19.

A cellular response can also play an important role and was not assessed in our study.

A recent study in Rituximab-treated patients 22 Gram-positive peritonitis has been reported by Hu et al. 26 . In contrast, after the first vaccine dose, a part of the population followed less strict pandemic-related rules 27 . Similarly, a supplementary vaccine dose could have increased patients' confidence in their protection, resulting in diminished carefulness in following aseptic technique. More studies are needed to confirm this observation, but it seems important to educate patients to maintain aseptic rules especially with patients who started peritoneal dialysis during the pandemic.

To our knowledge, this is the first study evaluating humoral response in both HD and PD patients systematically receiving a third dose of vaccine against SARS-CoV-2. Our study has some limitations. First, humoral response to a third dose was assessed in a single-center small-sized group, which limited statistical analyses and could induce bias. Second, we included patients with positive anti-nucleocapsid serology implying previous contact with SARS-CoV-2 but all patients with a history of symptomatic COVID-19 were excluded. This could induce biases because immunity elicited by infection vs. vaccine cannot clearly be differentiated. We chose to give 3 vaccine doses to patients with positive anti-nucleocapsid antibodies and without history of symptomatic COVID because COVID-19 serology was not mandatory or recommended before vaccination in dialysis patients. A third dose appears to have a diminished benefit in these patients who already developed good humoral response after two vaccine doses. Third, measurement of response to vaccination was only assessed using antibody levels, without taking into account cellular immunity or clinical outcomes.

Fourth, we did not compare our results to a control group in which individuals did not receive a third vaccine dose. Therefore, we could not analyze if the observed increase in antibody level was only due to the third vaccine dose or to a delayed immune response following the second vaccine dose. Nevertheless, recent studies showed relative stability of antibody titer J o u r n a l P r e -p r o o f 13 between two and three weeks after vaccination in dialysis patients 10 and serology was measured a median of 50 days after the second vaccine dose in our study. Fifth, there is no unequivocal means to assess increase in antibody titer and we used titer ratio as it is classically used in other studies evaluating vaccine efficacy. Yet, this could have disproportionately emphasized the effect for those who had a poor antibody response after the second vaccine dose. Finally, because of the observational nature of our study, there is a variability in the time between the administration of the second dose and serology, which may be a potential source of bias.

To conclude, a third dose of BNT162b2 vaccine substantially increased antibody level in dialysis patients, especially in patients with low antibody levels after the second dose and with a longer interval between second and third dose. In contrast, there was little evidence of an increase in antibody level after the third dose in patients with initial high anti-S1 antibodies or in those undergoing chemotherapy. Adverse events did not seem to be more common or severe following a third vaccine dose. Clinical efficacy of a third boost dose in dialysis patients remains to be determined. Figure S1 . Individual anti-S1 antibody titer according to dialysis modality.

Item S1: Questionnaire on vaccine reaction after the third vaccine dose. Table S1 . Non-and weak responders after the second vaccine dose. Table S2 . Patients without increase in antibody titer after the third vaccine dose. Figure S1 ; Item S1; Tables S1-S5.

Authors' contributions: Designed study and interpreted data: IB, PH, A-LF; performed statistical analyses: A-LF; collected anti-spike serology data: SA; performed anti-spike serology testing: SK; collected clinical and biological data: IB, PH, ALF, VC, AP, NV, D-FB, LH. Each author contributed important intellectual content during manuscript drafting or revision and agrees to be personally accountable for the individual's own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate. Support: This study was sponsored by the Centre Hospitalier Sud-Francilien, which did not have any role in study design, data collection, analysis, reporting, or the decision to submit for publication.

Financial Disclosure: The authors declare that they have no relevant financial interests. 

Novel coronavirus disease in patients with end-stage kidney disease

Vulnerabilities in kidney transplant recipients with COVID-19: a single center experience

Persistence of antibodies to pneumococcal vaccine in patients with chronic renal failure

Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study

Premature immune senescence and chronic kidney disease: Update and perspectives

Safety and Efficacy of the BNT162b2 mRNA Covid-19

Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis

Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy

Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won

Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients

Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients

Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients-a prospective cohort study

Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared to healthy controls

Vaccins contre la Covid-19: modalites d'administration des rappels

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

COVID-19 Vaccination in Haemodialysis Patients: Good things come in threes…

Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: A method comparison of two different commercially available serological assays from the same manufacturer

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

Kinetics of Anti-SARS-CoV-2 IgG Antibodies in Hemodialysis Patients Six Months after Infection

Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients

Changes before and after COVID-19 pandemic on the personal hygiene behaviors and incidence of peritonitis in peritoneal-dialysis patients: a multi-center retrospective study

Covid-19: Stronger warnings are needed to curb socialising after vaccination, say doctors and behavioural scientists

Ab after 2 nd dose, AU/ml 284

Results are shown as median [interquartile range] for continuous variables, or as number of patients (percentage) for categorical variables. Mann Whitney test and Fisher's exact test were used to compare continuous and categorical variables according to the dialysis modality

HD : hemodialysis

Spike protein S1; Ab, antibody

Acknowledgements: The authors thank patients for their participation to the study.Data Sharing: The data that support the findings of this study are available upon request.